-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

Benzinga·01/07/2026 20:13:13
語音播報
UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.